1. A 13-substituted methacycline compound of the formula:
30
wherein:
R4 and R4 are each alkyl;
R5 is hydrogen, hydroxyl, or a prodrug moiety;
R6 is a phenyl group, an alkoxyphenyl group, a halophenyl group, a carboxyphenyl group, an acylphenyl group, a cyanophenyl group, a nitrophenyl group, a naphthyl group, a dialkylphenyl group or an alkylphenyl group; a t-butyl group; or an aminoalkanethio group; and pharmaceutically acceptable salts thereof.
2. The compound of claim 1, wherein said 13-substituted methacycline compound is selected from the group consisting of 13-(phenyl) methacycline and 13-(4-chlorophenyl-5-cyclohexanoate) methacycline.
3. The compound of claim 1, wherein said 13-substituted methacycline compound is selected from the group consisting of 13-(4-methoxyphenyl) methacycline, 13-(methylenedioxyphenyl) methacycline, 13-(4-ethoxyphenyl) methacycline, 13-(p-carbomethoxyphenyl) methacycline, and 13-(3,4-methylenedioxyphenyl) methacycline.
4. The compound of claim 1, wherein said 13-substituted methacycline compound is selected from the group consisting of 13-(4-fluorophenyl) methacycline, 13-(4-chlorophenyl) methacycline, 13-(3-chlorophenyl) methacycline, 13-(methylenedioxyphenyl) methacycline, 13-(3-carboxylphenyl) methacycline, 13-(3-4-dichlorophenyl) methacycline, 13-(4-acetylphenyl) methacycline, 13-(4-ethoxyphenyl) methacycline, 13-(4-chlorophenyl-5-cyclohexanoate) methacycline, 13-(3,5-difluorophenyl) methacycline, 13-(3-acetylphenyl) methacycline, 13-(4-bromophenyl) methacycline, 13-(2,4-difluorophenyl) methacycline, 13-(2-chlorophenyl) methacycline, 13-(p-carbomethoxyphenyl) methacycline, and 13-(trifluoromethylphenyl) methacycline.
5. The compound of claim 1, wherein said 13-substituted methacycline compound is 13-(3-carboxylphenyl) methacycline.
6. The compound of claim 1, wherein said 13-substituted methacycline compound is selected from the group consisting of 13-(3-acetylphenyl) methacycline, 13-(4-acetylphenyl) methacycline, and 13-(3-formyl) methacycline.
7. The compound of claim 1, wherein said 13-substituted methacycline compound is 13-(p-cyanophenyl) methacycline.
8. The compound of claim 1, wherein said 13-substituted methacycline compound is 13-(4-nitrophenyl) methacycline.
9. The compound of claim 1, wherein said 13-substituted methacycline compound is 13-(naphthyl) methacycline.
10. The compound of claim 1, wherein said 13-substituted methacycline compound is 13-(3,5-dimethylphenyl) methacycline.
11. The compound of claim 1, wherein said 13-substituted methacycline compound is selected from the group consisting of 13-(p-t-butylphenyl) methacycline and 13-(p-tolyl) methacycline.
12. A 13-substituted methacycline compound, wherein said compound is 9,13-(di-t-butyl) methacycline.
13. The compound of claim 1, wherein said 13-substituted methacycline compound is 13-(dimethylaminoethanethio) methacycline.
14. A method for treating a tetracycline responsive state in a mammal, comprising administering to said mammal a 13-substituted methacycline compound of claim 1 or 12, such that said tetracycline responsive state is treated.
15. The method of claim 14, wherein said 13-substituted methacycline compound is selected from the group consisting of 13-(phenyl) methacycline, 13-(4-chlorophenyl-5-cyclohexanoate) methacycline, 13-(4-methoxyphenyl) methacycline, 13-(methylenedioxyphenyl) methacycline, 13-(4-ethoxyphenyl) methacycline, 13-(p-carbomethoxyphenyl) methacycline, 13-(3,4-methylenedioxyphenyl) methacycline, 13-(4-fluorophenyl) methacycline, 13-(4-chlorophenyl) methacycline, 13-(3-chlorophenyl) methacycline, 13-(methylenedioxyphenyl) methacycline, 13-(3-carboxylphenyl) methacycline, 13-(3-4-dichlorophenyl) methacycline, 13-(4-acetylphenyl) methacycline, 13-(4-ethoxyphenyl) methacycline, 13-(4-chlorophenyl-5-cyclohexanoate) methacycline, 13-(3,5-difluorophenyl) methacycline, 13-(3-acetylphenyl) methacycline, 13-(4-bromophenyl) methacycline, 13-(2,4-difluorophenyl) methacycline, 13-(2-chlorophenyl) methacycline, 13-(p-carbomethoxyphenyl) methacycline, 13-(trifluoromethylphenyl) methacycline, 13-(3-carboxylphenyl) methacycline, 13-(3-acetylphenyl) methacycline, 13-(4-acetylphenyl) methacycline, 13-(3-formyl) methacycline, 13-(p-cyanophenyl) methacycline, 13-(4-nitrophenyl) methacycline, 13-(naphthyl) methacycline, 13-(p-t-butylphenyl) methacycline, 13-(3,5-dimethylphenyl) methacycline, 13-(p-tolyl) methacycline, 9,13-di-t-butyl) methacycline, and 13-(dimethylaminoethanethio) methacycline.
16. The method of claim 14, wherein said tetracycline responsive state is a bacterial infection.
17. The method of claim 16, wherein said bacterial infection is associated with E. coli.
18. The method of claim 16, wherein said bacterial infection is associated with S. aureus.
19. The method of claim 16, wherein said bacterial infection is associated with E. faecalis.
20. The method of claim 16, wherein said bacterial infection is resistant to other tetracycline antibiotics.
21. The method of claim 14, wherein said compound is administered with a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising a therapeutically effective amount of a 13-substituted methacycline compound of claim 1 or 12 and a pharmaceutically acceptable carrier.
23. The pharmaceutical composition of claim 22, wherein said 13-substituted methacycline compound is selected from the group consisting of 13-(phenyl) methacycline, 13-(4-chlorophenyl-5-cyclohexanoate) methacycline, 13-(4-methoxyphenyl) methacycline, 13-(methylenedioxyphenyl) methacycline, 13-(4-ethoxyphenyl) methacycline, 13-(p-carbomethoxyphenyl) methacycline, 13-(3,4-methylenedioxyphenyl) methacycline, 13-(4-fluorophenyl) methacycline, 13-(4-chlorophenyl) methacycline, 13-(3-chlorophenyl) methacycline, 13-(methylenedioxyphenyl) methacycline, 13-(3-carboxylphenyl) methacycline, 13-(3-4-dichlorophenyl) methacycline, 13-(4-acetylphenyl) methacycline, 13-(4-ethoxyphenyl) methacycline, 13-(4-chlorophenyl-5-cyclohexanoate) methacycline, 13-(3,5-difluorophenyl) methacycline, 13-(3-acetylphenyl) methacycline, 13-(4-bromophenyl) methacycline, 13-(2,4-difluorophenyl) methacycline, 13-(2-chlorophenyl) methacycline, 13-(p-carbomethoxyphenyl) methacycline, 13-(trifluoromethylphenyl) methacycline, 13-(3-carboxylphenyl) methacycline, 13-(3-acetylphenyl) methacycline, 13-(4-acetylphenyl) methacycline, 13-(3-formyl) methacycline, 13-(p-cyanophenyl) methacycline, 13-(4-nitrophenyl)) methacycline, 13-(naphthyl) methacycline, 13-(p-t-butylphenyl) methacycline, 13-(3,5-dimethylphenyl) methacycline, 13-(p-tolyl) methacycline, 9,13-di-t-butyl) methacycline, and 13-(dimethylaminoethanethio) methacycline.
24. A method for synthesisizing a 13-substituted methacycline compound, comprising contacting a methacycline compound with a boronic acid, under appropriate conditions such that a 13-substituted methacycline compound is formed.
25. The method of claim 24, wherein said appropriate conditions comprise a transition metal catalyst.
26. The method of claim 25, wherein said transition metal catalyst is a palladium catalyst.
27. The method of claim 24, wherein said boronic acid is an aryl boronic acid.
28. A method for synthesizing a 13-substituted methacycline compound, comprising contacting a methacycline compound with a tertiary alcohol, under appropriate conditions such that a 13-substituted methacycline compound is synthesized.
29. The method of claim 28, wherein said appropriate conditions comprise an acid catalyst.
30. The method of claim 28, wherein the 13-substituted methacycline compound is substituted with an alkyl group at the 13 position.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-23. (canceled)
24. A secured token comprising:
an applet providing a set of common commands and operable to be instantiated to create a plurality of applet instances; and
specification logic allowing specification of file structures, security conditions, and access conditions for each applet instance in the plurality of applet instances.
25. The secured token of claim 24, wherein the secured token is a smartcard.
26. The secured token of claim 24, wherein the applet is a first applet, the secured token further comprising a second applet providing a second set of common commands, the second set of common commands including the first set of common commands and additional commands to provide additional services.
27. The secured token of claim 24, wherein an applet instance is associated with a subset of the set of common commands.
28. The secured token of claim 24, wherein the set of common commands includes a select command for selecting a desired applet instance, a retrieve command for retrieving information from a desired applet instance, a file read command for reading data from a desired file, a record read command for reading data from a desired record in a file, a file update command for updating data in a desired file, a record update command for updating a desired record, and a verify passcode command for verifying the passcode in order to access the secured token.
29. The secured token of claim 24, wherein the set of common commands includes a get status command for retrieving information detailing an internal status of the corresponding applet, and wherein the second set of commands includes a get status command for retrieving information detailing an internal status of the corresponding applet, an internal authenticate command for providing credential management services for incoming data, a change passcode command for modifying the passcode used for accessing the secured token, and an unblock passcode command for unblocking the passcode.
30. A method comprising:
providing an applet on a secured token, the applet providing a set of common commands; and
instantiating a plurality of applet instances, including a first applet instance for a first application, utilizing the set of commands, wherein the set of common commands specifies file structures, security conditions, and access conditions for each applet instance in the plurality of applet instant.
31. The method of claim 30 further comprising:
providing the secured token, wherein the secured token is a smartcard.
32. The method of claim 30, wherein the applet is a first applet, the secured token further comprising a second applet providing a second set of common commands, the second set of common commands including the first set of common commands and additional commands to provide additional services.
33. The method of claim 32 further comprising utilizing at least one cryptographic service provided by the second set of common commands and utilizing a signature selected from the group consisting of DES-MAC and RSA signatures.
34. The method of claim 30 further comprising using the first application in a client to interact with the first applet instance.
35. The method of claim 30 further comprising protecting a communication with the secured token by secure messaging.
36. The method of claim 30 further comprising using the secured token for financial transactions.
37. A method comprising:
communicating, using a client, with an applet on a secured token, the applet providing a set of common commands, wherein the secured token includes a plurality of applet instances, including a first applet instance for a first application of the client, the set of common commands specifying file structures, security conditions, and access conditions for each applet instance in the plurality of applet instant.
38. The method of claim 37, further comprising selecting, using the client, which commands in the set of common commands is available to the first applet instance.
39. The method of claim 37 further comprising:
obtaining the secured token, wherein the secured token is a smartcard.
40. The method of claim 37 further comprising protecting the communication with the secured token by secure messaging.
41. The method of claim 37 further comprising conducting a financial transaction with the secured token.